

IMAGE



Infographic: Ranibizumab plus panretinal photocoagulation (PRP) versus PRP alone for high-risk proliferative diabetic retinopathy (PDR): the PROTEUS study

Imran H. Yusuf^{1,2}, Christin Henein^{3,4} and Sobha Sivaprasad⁴


© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2023

Eye; <https://doi.org/10.1038/s41433-023-02399-x>

Exclusions included patients with HBA1c > 11%, systolic blood pressure > 170 mmHg, or diastolic > 100 mmHg, intraocular surgery in the preceding 6 months including laser treatments, anti-VEGF in the preceding 3 months, or lesions involving the central macula, such as macular oedema (central retinal thickness > 300 µm). Baseline characteristics were similar, except for age (greater in the combined group). Assessments were undertaken by colour fundus photography and fluorescein angiography at months 3, 7 and 12, and assessed by masked graders. Retreatment in either group was at the investigator's discretion, and involved a combination of

ranibizumab injection and PRP in the combined treatment group. There were no significant differences in BCVA at any timepoint between groups. Reduction in neovascularization was defined as any decrease in area from baseline to month 12. Vitrectomy rates did not differ between treatment groups ($P = 0.12$). No deaths or unexpected adverse events were reported.

PRP – panretinal photocoagulation; PDR – proliferative diabetic retinopathy; DM – diabetes mellitus; BCVA – best corrected visual acuity; NVD – neovascularisation of the optic disc; NVE – neovascularisation elsewhere in the retina.



¹Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK. ²Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford OX3 9DU, UK. ³UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. ⁴NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. ✉email: Imran.yusuf@eye.ox.ac.uk

Received: 6 December 2022 Revised: 13 December 2022 Accepted: 13 January 2023

Published online: 21 April 2023

Reference: Figueira et al, "Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)" *Ophthalmology*, 2018;125:691–700.

FUNDING

Medical Research Council UK (MR/R000735/1).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Imran H. Yusuf.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Please note that the infographic is best viewed online.